12th March 2018 PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency. ARO-AAT is the first clinical candidateContinue Reading

February 22, 2018 07:30 AM Eastern Standard Time PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which is beingContinue Reading

MENLO PARK, Calif., Feb. 26, 2018 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today announced the completion of dosing and evaluation of patients (n=2) in the first cohort of the ADVANCE Phase 1/2 clinical trialContinue Reading

Arrowhead Pharmaceuticals Inc. announced last week that the company’s second-generation investigational medicine ARO-AAT was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). ARO-AAT is being developed for the treatment of a rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Alpha-1 antitrypsin deficiency (AATD) is aContinue Reading

Kamada Ltd. (NASDAQ: KMDA) today announced a collaboration with the Mount Sinai Acute GvHD International Consortium (MAGIC) to conduct a proof-of-concept clinical trial assessing the safety and preliminary efficacy of Kamada’s Alpha-1-Antitrypsin (AAT) as preemptive therapy for patients at high-risk for the development of steroid-refractory acute GvHD (SR-aGvHD). The study willContinue Reading